Publication date: Available online 22 November 2018
Source: Trends in Endocrinology & Metabolism
Author(s): Shiva Ganjali, Biagio Ricciuti, Matteo Pirro, Alexandra E. Butler, Stephen L. Atkin, Maciej Banach, Amirhossein Sahebkar
Cancer is the second leading cause of death in western countries, and thus represents a major global public health issue. Whilst it is well-recognized that diet, obesity, and smoking are risk factors for cancer, the role of low levels of high-density lipoprotein cholesterol (HDL-C) in cancer is less well appreciated. Conflicting evidence suggests that serum HDL-C levels may be either positively or negatively associated with cancer incidence and mortality. Such disparate associations are supported in part by the multitude of high-density lipoprotein (HDL) functions that can all have an impact on cancer cell biology. The aim of this review is to provide a comprehensive overview of the crosstalk between HDLs and cancer, focusing on the molecular mechanisms underlying this association.
https://ift.tt/2KqKiL1
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου